文献速递肝病

维生素E与二十二碳六烯酸乙酯对代谢功能障碍相关脂肪性肝病的影响:一项随机双盲安慰剂对照平行组临床试验(PUVENAFLD)

The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD).
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-12

该随机双盲安慰剂对照试验将203例代谢功能障碍相关脂肪性肝病患者按2:1:1:2随机分为维生素E联合DHA组、维生素E单药组、DHA单药组和安慰剂组,干预6个月。结果显示联合组、维生素E单药组及DHA单药组在降低肝脏脂肪分数方面与安慰剂相比均无显著差异,转氨酶水平亦无统计学显著差异。

要点

  • 维生素E联合DHA、维生素E单药或DHA单药均未显著降低MRI-PDFF评估的肝脏脂肪分数。
  • 三种干预在3个月或6个月时ALT和AST水平与安慰剂相比均无统计学显著差异。
  • 作者指出该试验针对上述分析把握度不足。

核心结论

  • 维生素E联合DHA或任一单药在研究的代谢功能障碍相关脂肪性肝病人群中未显示出降低肝脏脂肪或转氨酶的疗效。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组临床试验,纳入203例代谢功能障碍相关脂肪性肝病成人患者,按2:1:1:2随机分为维生素E 1000 mg/天联合DHA 1.89 g/天组、维生素E 1000 mg/天单药组、DHA 1.89 g/天单药组和安慰剂组,干预6个月。

主要发现

  • 队列平均年龄51岁,女性占53%,白人占91%,西班牙裔占59%。
  • 维生素E联合DHA组对主要终点即MRI-PDFF评估的肝脏脂肪分数较基线的降低无效果(p=0.98)。
  • 维生素E单药组(p=0.91)和DHA单药组(p=0.14)与安慰剂相比均未显著降低肝脏脂肪分数。
  • 三个干预组在3个月或6个月时ALT(U/L)或AST(U/L)水平与安慰剂相比均未检测到统计学显著差异。

局限性

  • 作者指出该试验针对维生素E单药和DHA单药与安慰剂比较的分析把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We conducted a clinical trial to determine the efficacy of the combination of vitamin E and/or docosahexaenoic acid (DHA) versus placebo in reducing liver fat content after 6 months of intervention in adults with MASLD. METHODS: Adults with MASLD were randomised to one of four treatment arms (vitamin E 1000 mg/daily + DHA 1.89 g/daily or combination arm, vitamin E 1000 mg alone, DHA 1.89 g alone or placebo) following a 2:1:1:2 randomisation. The primary objective was to determine the efficacy of DHA + vitamin E versus placebo in reducing hepatic fat fraction (%) relative to baseline after 6 months of intervention. Secondary objectives were to determine the effect of vitamin E or DHA alone versus placebo on reducing liver fat at 6 months. RESULTS: Our cohort consisted of 203 subjects with a mean age of 51 years, 53% female, 91% White, 59% Hispanic ethnicity. The combination of vitamin E + DHA had no effect on the primary endpoint of reducing hepatic steatosis as determined by MRI-PDFF (p = 0.98). Neither vitamin E alone (p = 0.91) nor DHA alone (p = 0.14) significantly reduced hepatic steatosis compared to placebo. However, the trial was not powered adequately for this analysis. Compared with placebo, no statistically significant differences were detected in the 3-month or 6-month levels for ALT (U/L) or AST (U/L) in all three intervention groups. CONCLUSIONS: The combination of DHA + vitamin E or either agent alone did not demonstrate efficacy on reducing liver fat or aminotransferases in the studied population.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Alkhouri N, McCarthy D, Bayne AV, et al. The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD). Aliment Pharmacol Ther. 2024. PMID: 39001559. doi:10.1111/apt.18149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。